参考文献/References:
[1] Hanahan D, Weinberg RA. Hallmarks of cancer:the next generation[J]. Cell, 2011, 144(5):646-674. DOI:10.1016/j.cell.2011.02.013.
[2] Moreno Garcia V, Basu B, Molife LR, et al. Combining antiangiogenics to overcome resistance:rationale and clinical experience[J]. Clin Cancer Res, 2012, 18(14):3750-3761. DOI:10.1158/1078-0432.CCR-11-1275.
[3] Eng L, Azad AK, Habbous S, et al.Vascular endothelial growth factor pathway polymorphisms as prognostic and pharmacogenetic factors in cancer:a systematic review and meta-analysis[J]. Clin Cancer Res, 2012,18(17):4526-4537. DOI:10.1158/1078-0432.CCR-12-1315.
[4] Desar IM, van Herpen CM, van Laarhoven HW, et al. Beyond RECIST:molecular and functional imaging techniques for evaluation of response to targeted therapy[J]. Cancer Treat Rev, 2009, 35(4):309-321. DOI:10.1016/j.ctrv.2008.12.001.
[5] 杨明福,李前伟. 肿瘤血管内皮生长因子受体核素显像研究现状[J].国际放射医学核医学杂志, 2010, 34(1):19-22. DOI:10.3760/cma.j.issn.1673-4114.2010.01.005. Yang MF,Li QW. Review present study on vascular endothelial growth factor receptor imaging[J]. Int J Radiat Med Nucl Med, 2010, 34(1):19-22.
[6] Cai W, Chen K, Mohamedali KA, et al. PET of vascular endothelial growth factor receptor expression[J]. J Nucl Med, 2006, 47(12):2048-2056.
[7] Lee I, Yoon KY, Kang CM, et al. Evaluation of the angiogenesis inhibitor KR-31831 in SKOV-3 tumor-bearing mice using 64Cu-DOTA-VEGF121 and micro PET[J]. Nucl Med Biol, 2012, 39(6):840-846. DOI:10.1016/j.nucmedbio.2012.01.007.
[8] Blankenberg FG, Backer MV, Levashova Z, et al. In vivo tumor angiogenesis imaging with site-specific labeled 99mTc-HYNIC-VEGF[J]. Eur J Nucl Med Mol Imaging, 2006, 33(7):841-848. DOI:10.1007/s00259-006-0099-1.
[9] Levashova Z, Backer M, Hamby CV, et al. Molecular imaging of changes in the prevalence of vascular endothelial growth factor receptor in sunitinib-treated murine mammary tumors[J]. J Nucl Med, 2010, 51(6):959-966. DOI:10.2967/jnumed.109.072199.
[10] Blankenberg FG, Levashova Z, Sarkar SK, et al. Noninvasive assessment of tumor VEGF receptors in response to treatment with pazopanib:a molecular imaging study[J]. Transl Oncol, 2010, 3(1):56-64. DOI:10.1593/tlo.09271.
[11] Nagengast WB, Lub-De Hooge MN, Oosting SF, et al. VEGF-PET imaging is a noninvasive biomarker showing differential changes in the tumor during sunitinib treatment[J]. Cancer Res, 2011, 71(1):143-153. DOI:10.1158/0008-5472.CAN-10-1088.
[12] Meyer JP, Edwards KJ, Kozlowski P, et al. Selective imaging of VEGFR-1 and VEGFR-2 using 89Zr-labeled single-chain VEGF mutants[J]. J Nucl Med, 2016, 57(11):1811-1816. DOI:10.2967/jnumed.116.173237.
[13] Stollman TH, Scheer MG, Franssen GM, et al. Tumor accumulation of radiolabeled bevacizumab due to targeting of cell-and matrix-associated VEGF-A isoforms[J]. Cancer Biother Radiopharm, 2009, 24(2):195-200. DOI:10.1089/cbr.2008.0574.
[14] Scheer MG, Stollman TH, Boerman OC, et al. Imaging liver metastases of colorectal cancer patients with radiolabelled bevacizumab:Lack of correlation with VEGF-A expression[J]. Eur J Cancer, 2008, 44(13):1835-1840. DOI:10.1016/j.ejca.2008.05.026.
[15] 邵国强, 王自正. 整合素αvβ3受体靶向肿瘤显像研究进展[J].国际放射医学核医学杂志, 2014, 38(1):33-36. DOI:10.3760/cma.j.issn.1673-4114.2014.01.007. Shao GQ, Wang ZZ. Integrin αvβ3 targeted tumor imaging[J]. Int J Radiat Med Nucl Med, 2014, 38(1):33-36.
[16] Axelsson R, Bach-Gansmo T, Castell-Conesa J, et al. An open-label, multicenter, phase 2a study to assess the feasibility of imaging metastases in late-stage cancer patients with the αvβ3-selective angiogenesis imaging agent 99mTc-NC100692[J]. Acta Radiol, 2010,51(1):40-46. DOI:10.3109/02841850903273974.
[17] Weis SM, Cheresh DA. αv integrins in angiogenesis and cancer[J/OL]. Cold Spring Harb Perspect Med, 2011, 1(1):a006478[2017-01-01]. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3234453/.DOI:10.1101/cshperspect.a006478.
[18] 岳宁, 袁双虎, 杨国仁. RGD分子影像在肺癌的研究现状与进展[J].中国肺癌杂志, 2014, 17(12):855-858. DOI:10.3779/j.issn.1009-3419.2014.12.06. Yue N, Yuan SH, Yang GR. Status and advances of RGD molecular imaging in lung cancer[J]. Chin J Lung Cancer, 2014, 17(12):855-858.
[19] 邵国强, 杨瑞, 梁凯, 等. 99Tcm-3P4-RGD2 microSPECT/CT显像评价抗新生血管治疗肿瘤疗效价值的实验研究[J]. 中华放射医学与防护杂志, 2017, 37(1):12-18. DOI:10.3760/cma.j.issn.0254-5098.2017.01.003. Shao GQ, Yang R, Liang K. Study on 99Tcm-3P4-RGD2 micro SPECT/CT imaging to anti-angiogensis therapeutic effect[J]. Chin J Radiol Med Prot, 2017, 37(1):12-18.
[20] Haubner R, Weber WA, Beer AJ, et al. Noninvasive visualization of the activated alphavbeta3 integrin in cancer patients by positron emission tomography and 18F Galacto-RGD[J/OL]. PLoS One, 2005, 2(3):e70[2017-05-01].http://journals.plos.org/plosmedicine/article/file?id=10.1371/journal.pmed.0020070&type=printable.DOI:10.1371/journal.pmed.0020070.
[21] Chen H, Niu G, Wu H, et al. Clinical application of radiolabeled RGD peptides for PET imaging of integrin αvβ3[J]. Theranostics,2016, 6(1):78-92. DOI:10.7150/thno.13242.
[22] Doss M, Kolb HC, Zhang JJ, et al. Biodistribution and radiation dosimetry of the integrin marker 18F-RGD-K5 determined from whole-body PET/CT in monkeys and humans[J]. J Nucl Med, 2012, 53(5):787-795. DOI:10.2967/jnumed.111.088955.
[23] Battle MR, Goggi JL, Allen L, et al.Monitoring tumor response to antiangiogenic sunitinib therapy with 18F-fluciclatide, an 18F-labeled αvβ3-integrin and αvβ5-integrin imaging agent[J]. J Nucl Med,2011, 52(3):424-430. DOI:10.2967/jnumed.110.077479.
[24] Janssen ML, Oyen WJ, Dijkgraaf I, et al. Tumor targeting with radiolabeled αvβ3 integrin binding peptides in a nude mouse model[J]. Cancer Res, 2002, 62(21):6146-6151.
[25] Liu S. Radiolabeled cyclic RGD peptide bioconjugates as radiotracers targeting multiple integrins[J]. Bioconjug Chem, 2015, 26(8):1413-1438. DOI:10.1021/acs.bioconjchem.5b00327.
[26] Wang K, Seo BR, Fischbach C, et al. Fibronectin mechanobiology regulates tumorigenesis[J]. Cell Mol Bioeng, 2016, 9:1-11. DOI:10.1007/s12195-015-0417-4.
[27] Berndorff D, Borkowski S, Moosmayer D, et al. Imaging of tumor angiogenesis using 99mTc-labeled human recombinant anti-ED-B fibronectin antibody fragments[J]. J Nucl Med, 2006, 47(10):1707-1716.
[28] Yoshimoto M, Kurihara H, Fujii H, et al. Theragnostic imaging using radiolabeled antibodies and tyrosine kinase inhibitors[J/OL]. Scientific World J, 2015, 2015:842101[2017-05-01]. https://www.researchgate.net/publication/276159365_Theragnostic_Imaging_Using_Radiolabeled_Antibodies_and_Tyrosine_Kinase_Inhibitors.DOI:10.1155/2015/842101.
[29] Jung KH, Lee KH. Molecular imaging in the era of personalized medicine[J]. J Pathol Transl Med, 2015, 49(1):5-12. DOI:10.4132/jptm.2014.10.24.
[30] Mees G, Dierckx R, Mertens K, et al. 99mTc-labeled t ricarbonyl his-CNA35 as an imaging agent for the detection of tumor vasculature[J]. J Nucl Med, 2012, 53(3):464-471. DOI:10.2967/jnumed.111. 095794.
相似文献/References:
[1]黄建敏,解朋,刘晓梅,等.以整合素αvβ3为靶点的肿瘤分子显像及靶向治疗[J].国际放射医学核医学杂志,2015,39(3):256.[doi:10.3760/cma.j.issn.1673-4114.2015.03.015]
Huang Jianmin,Xie Peng,Liu Xiaomei,et al.Integrins αvβ3 in molecular imaging and targeted therapy of neoplasms[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(5):256.[doi:10.3760/cma.j.issn.1673-4114.2015.03.015]
[2]邵国强,王自正.整合素αvβ3受体靶向肿瘤显像研究进展[J].国际放射医学核医学杂志,2014,38(1):33.[doi:10.3760/cma.j.issn 1673-4114.2014.01.007]
Shao Guoqiang,Wang Zizheng.Integrin αvβ3 targeted tumor imaging[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(5):33.[doi:10.3760/cma.j.issn 1673-4114.2014.01.007]
[3]郝玉美,贺欣,宋娜玲.靶向肿瘤新生血管整合素αvβ3受体显像研究现状及进展[J].国际放射医学核医学杂志,2014,38(3):179.[doi:10.3760/cma.j.issn.1673-4114.2014.03.010]
Hao Yumei,He Xin,Song Naling.Progress on tumor angiogenesis imaging targeting integrin αvβ3 receptor[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(5):179.[doi:10.3760/cma.j.issn.1673-4114.2014.03.010]
[4]赵龙,罗作明,孙龙,等.新型αvβ3和Neuropilin-1双靶点正电子成像探针18F-FAl-NOTA-RGD-ATWLPPR用于脑胶质瘤的PET显像研究[J].国际放射医学核医学杂志,2017,41(4):233.[doi:10.3760/cma.j.issn.1673-4114.2017.04.001]
Zhao Long,Luo Zuoming,Sun Long,et al.Imaging of glioma with an integrin αvβ3 and neuropilin-1 dual-targeted PET probe 18F-FAl-NOTA-RGD-ATWLPPR[J].International Journal of Radiation Medicine and Nuclear Medicine,2017,41(5):233.[doi:10.3760/cma.j.issn.1673-4114.2017.04.001]